Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Shattuck Labs, Inc.

35 indications, side-by-side phase, drug & LoA

$4.13

-0.28 (-6.55%)

D 37Pipeline Score Overvalued Biotech · Clinical
Market Cap
467.75 M
EPS
-0.64
P/E Ratio
-
Value Trade
1.78 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • Revenue

    -

  • R&D Expenses

    10.95 M

  • Operating CF

    -13.42 M

  • Total Assets

    102.12 M

  • Total Liabilities

    6.29 M

  • Equity

    95.83 M

  • D/E Ratio

    12,345

-6.44 %
Week
-21.99 %
1 Month
52.5 %
3 Month
221.05 %
6 Month
-77.53 %
5 Year
-72.4 %
All Time
Cash Data
Stable

  • Cash Position

    102.12 M

  • Monthly Burn

    4.47 M

  • Runway

    21.7 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 7, 2026
Overview
Volume
2.17 M
52 Week Range
0.71 - 8.33
% held by Insiders
14.38 %
% held by Institutions
64.93 %
Enterprise Value
380.22 M
Total Shares
75.42 M
Short %
2.14 %
Float Shares
53.77 M
Company Description
HQ: 500 W. 5TH STREET, AUSTIN, TX,...
Employees:40
https://www.shattucklabs.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 1 data readout example
Phase 1
—
Biologics
Digestive System
Phase 1
—
Biologics
Digestive System
Phase 1
—
Biologics
Digestive System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D37
Pipeline Score
$120M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
Top 45%
Micro Cap
(rank 499 of 905)
Percentile Rank
Shattuck Labs, Inc. faces pipeline headwinds (37/100), with $499M risk-adjusted pipeline value, led by SL-325 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
SL-325
Monoclonal antibody		Healthy VolunteersPhase 1NCT0715843726% $252M ACTIVE NOT_RECRUITING 72 AVERAGE B (65) Jul 1, 2026LOW_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in STTK
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
STTK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STTK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STTK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
STTK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
STTK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Shattuck Labs, Inc. (STTK) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How STTK ranks across every disease it competes in
No competitive intelligence available for STTK.